Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 5, 2005, Pages 1400-1412

  Van Waes, Carter ^a   Chang, Angela A ^a   Lebowitz, Peter F ^b   Druzgal, Colleen H ^a   Chen, Zhong ^a   Elsayed, Yusri A ^b   Sunwoo, John B ^a   Rudy, Susan F ^a   Morris, John C ^b   Mitchell, James B ^b   Camphausen, Kevin ^b   Gius, David ^b   Adams, Julian ^c   Sausville, Edward A ^b   Conley, Barbara A ^b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Head and neck squamous cell carcinoma; Nuclear factor B; Proteasome; Radiotherapy

Indexed keywords

BIOPSY; BLOOD; DOSIMETRY; ENZYME INHIBITION; GENES; RADIOTHERAPY; TUMORS;

BORTEZOMIB; HEAD-AND-NECK SQUAMOUS CELL CARCINOMA (HNSCC); NUCLEAR FACTOR-ΚB; PROTEASOME;

ONCOLOGY;

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; SYNAPTOTAGMIN;

AGED; AIRWAY OBSTRUCTION; ANEMIA; APOPTOSIS; ARTICLE; ATAXIA; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; GENE TARGETING; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; LEUKOPENIA; LYMPHEDEMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DERMATITIS; RADIATION DOSE; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TUMOR BIOPSY; ULCER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, SQUAMOUS CELL; CYTOKINES; FEMALE; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; PROTEASE INHIBITORS; PYRAZINES; STOMATITIS; TRANSCRIPTION FACTOR RELA;

EID: 27744515028     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.05.007     Document Type: Article

References (42)

1. A. Jemal, T. Murray, A. Samuels Cancer statistics, 2003 CA Cancer J Clin 53 2003 5 26
2. D.I. Rosenthal, K.K. Ang Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma Semin Radiat Oncol 14 2004 153 166
3. J. Kao, M.C. Garofalo, M.T. Milano Re-irradiation of recurrent and second primary head and neck malignancies A comprehensive review Cancer Treat Rev 29 2003 21 30
4. S. Spencer, R. Wheeler, G. Peters Phase I trial of combined chemotherapy and re-irradiation for recurrent unresectable head and neck cancer Head Neck 25 2003 118 122
5. S.A. Spencer, J. Harris, R.H. Wheeler RTOG 96-10 Re-irradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck Int J Radiat Oncol Biol Phys 51 2001 1299 1304
6. R. DeCrevoisier, J. Bourhis, C. Conenge Full-dose re-irradiation for unresectable head and neck carcinoma experience at the Gustave-Roussy Institute in a series of 169 patients J Clin Oncol 16 1998 3556 3562
7. F.G. Ondrey, G. Dong, J. Sunwoo Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines Mol Carcinog 26 1999 119 129
8. D.C. Duffey, Z. Chen, G. Dong Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo Cancer Res 59 1999 3468 3474
9. G. Dong, Z. Chen, T. Kato The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma Cancer Res 59 1999 3495 3504
10. G. Dong, E. Loukinova, Z. Chen Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-κB signal pathway Cancer Res 61 2001 4797 4808
11. A. Loercher, T.L. Lee, J.L. Ricker Nuclear Factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma Cancer Res 64 2004 6511 6523
12. D.C. Duffey, C.V. Crowl-Bancroft, Z. Chen Inhibition of transcription factor nuclear factor-κB by a mutant inhibitor-κBα attenuates resistance of human head and neck squamous cell carcinoma to TNF-alpha caspase-mediated cell death Br J Cancer 83 2000 1367 1374
13. T. Kato, D.C. Duffey, F.G. Ondrey Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB Head Neck 22 2000 748 759
14. J. Adams The proteasome structure, function, and role in the cell Cancer Treat Rev 29 Suppl. 1 2003 3 9
15. B.A. Teicher, G. Ara, R. Herbst The proteasome inhibitor PS-341 in cancer therapy Clin Cancer Res 5 1999 2638 2645
16. J. Adams, V.J. Palombella, E.A. Sausville Proteasome inhibitors A novel class of potent and effective antitumor agents Cancer Res 59 1999 2615 2622
17. J.B. Sunwoo, Z. Chen, G. Dong Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin Cancer Res 7 2001 1419 1428
18. A.A. Chang, Z. Chen, J.L. Ricker Induction of apoptosis and regulation of inhibitor of apoptosis protein-1 and cyclin D1 expression in head and neck cancer cell lines by PS-341/bortezomib (VELCADE), a novel proteasome inhibitor [Abstract] Proc Am Assoc Cancer Res 95 2004 4007
19. C. Van Waes, J.B. Sunwoo, W. DeGraff Radiosensitization and proteasome inhibition J. Adams Cancer drug discovery and development Proteasome inhibitors in cancer therapy 2004 Humana Press Totowa, NJ 123 131
20. R.Z. Orlowski, A.S. Baldwin Jr NF-κB as a therapeutic target in cancer Trends Mol Med 8 2002 385 389
21. J.C. Cusack Jr, R. Liu, M. Houston Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341 Implications for systemic nuclear factor-κB inhibition Cancer Res 61 2001 3535 3540
22. S.M. Russo, J.E. Tepper, A.S. Baldwin Jr Enhancement of radiosensitivity by proteasome inhibition Implications for a role of NF-κB Int J Radiat Oncol Biol Phys 50 2001 183 193
23. P.F. Bross, R. Kane, A.T. Farrell Approval summary for bortezomib for injection in the treatment of multiple myeloma Clin Cancer Res 10 2004 3954 3964
24. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
25. W.H. McBride, K.S. Iwamoto, R. Syljuasen The role of the ubiquitin/proteasome system in cellular responses to radiation Oncogene 22 2003 5755 5773
26. W.H. McBride, F. Pajonk, C.S. Chiang NF-kappa B, cytokines, proteasomes, and low-dose radiation exposure Mil Med 167 Suppl. 2 2002 66 67
27. P.J. Elliott, T.A. Soucy, C.S. Pien Assays for proteasome inhibition Methods Mol Med 85 2003 163 172
28. Z. Chen, P.S. Malhotra, G. Thomas Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer Clin Cancer Res 5 1999 1369 1379
29. Y. Sharabi, R. Dendi, C. Holmes Baroreflex failure as a late sequela of neck irradiation Hypertension 42 2003 110 116
30. V.A. Papadimitrakopoulou, J. Izzo, L. Mao Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract Role in response to chemoprevention and cancer development Clin Cancer Res 7 2001 3127 3134
31. D.C. Guttridge, C. Albanese, J.Y. Reuther NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1 Mol Cell Biol 19 1999 5785 5799
32. C.Y. Wang, M.W. Mayo, R.G. Korneluk NF-κB antiapoptosis Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation Science 281 1998 1680 1683
33. L. Sevilla, A. Zaldumbide, P. Pognonec Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFκB, STAT and AP1 transcription factor families Histol Histopathol 16 2001 595 601
34. T. Berghmans, M. Paesmans, J.-J. Body A prospective study on hyponatremia in medical cancer patients Epidemiology, aetiology and differential diagnosis Support Care Cancer 8 1999 192 197
35. R.Z. Orlowski, T.E. Stinchcombe, B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 2002 4420 4427
36. J. Cortes, D. Thomas, C. Koller Phase I study of bortezomib in refractory or relapsed leukemias Clin Cancer Res 10 2004 3371 3376
37. A.M. Davies, P.N. Lara, D.H. Lau The proteasome inhibitor, bortezomib, in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer (NSCLC) Final report of a phase I California Cancer Consortium Study [Abstract] Proc Am Soc Clin Oncol 23 2004 639a
38. S. Iqbal, S. Cole, D. Yang Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors [Abstract] Proc Am Soc Clin Oncol 23 2004 141a
39. S.H. Hong, F.G. Ondrey, I.M. Avis Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6 A general role for inflammation? FASEB J 14 2000 1499 1507
40. V. Sriuranpong, J.I. Park, P. Amornphimoltham Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system Cancer Res 63 2003 2948 2956
41. T. Hideshima, D. Chauhan, P. Richardson NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 2002 16639 16647
42. N. Mitsiades, C.S. Mitsiades, V. Poulaki Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci USA 99 2002 14374 14379